- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02445976
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- University of Alabama
-
-
Arizona
-
Scottsdale, Arizona, United States, 85054
- Mayo Clinic
-
-
California
-
Los Angeles, California, United States, 90095
- University of California at Los Angeles
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Jacksonville
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- GU Research Network
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- New Mexico Cancer Care Alliance
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Carolina Urologic Research Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
Hampton, Virginia, United States, 23666
- Virginia Oncology Associates
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53715
- University of Wisconsin Carbone Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subjects must be ≥18 years of age.
- Subjects or their legal representatives must be able to provide written informed consent.
- Subjects must have documented histological or cytological evidence of adenocarcinoma of the prostate.
- Subjects must have an ECOG Performance Score of 0-1.
- Subjects must have undergone orchiectomy, or have ongoing LHRH analogue therapy prior to drug initiation. Subjects on LHRH analogues must remain on these agents for the duration of the study.
Subjects must have castrate levels of testosterone (≤50 ng/dl [1.7 nmol/L]) and have progressive disease at Screening defined as PSA rise determined by a minimum of 2 rising PSA values ≥1 week between each assessment. The PSA value at the Screening visit must be ≥2ng/mL with or without:
- Soft tissue disease progression defined by RECIST 1.1 at Screening or ≤ 28 days of C1D1. Measurable disease is not required for entry. Lymph nodes ≥ 1.5cm (short axis) are considered measurable disease (PCWG3)
- Bone disease progression defined by ≥2 new lesions on bone scan at Screening, or ≤28 days of C1D1
- Subjects must have received abiraterone and/or enzalutamide. Subject must have received either abiraterone or enzalutamide for ≥12 weeks. Other second generation CYP17 inhibitors/androgen receptor antagonists including but not limited to TAK-700 (orteronel), TOK-001 (galeterone) may have been taken in place of abiraterone and ARN-509 (apalutamide) may have been taken in place of enzalutamide.
Subjects must have adequate hematopoietic function as evidenced by:
- WBC ≥3,000/µl
- ANC ≥1,500/µl
- Platelet count ≥100,000/µl
- HGB ≥10 g/dl and not transfusion dependent
Subjects must have adequate liver function, including all of the following:
- Total serum bilirubin ≤2.0 x ULN unless the subject has documented Gilbert syndrome;
- Aspartate and alanine aminotransferase (AST & ALT) ≤3.0 x ULN or ≤5.0 x ULN if subject has liver metastasis;
- Alkaline phosphatase ≤2.0 x ULN or ≤5 x ULN in case of bone metastasis and/or hepatic metastasis
- Subjects must have adequate renal function as evidenced by a serum creatinine of <2.0 mg/dl.
- Subjects must have potassium (K+) >3.5 mEq/l.
- Subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting a Screening and continuing throughout the study period and for 3 months after final study drug administration • Two acceptable forms of birth control include:
1. Condom (barrier method of contraception), and 2. One of the following:
- Oral, injected or implanted hormonal contraception
- Placement of an intrauterine device (IUD) or intrauterine system (ISU)
- Additional barrier methods of contraception: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
- Vasectomy or surgical castration ≥ 6 months prior to Screening. 13. Subjects able to swallow study medication 14. Subjects able to comply with study requirements
Exclusion Criteria
- Subjects who have completed sipuleucel-T (Provenge ®) treatment within 28 days of study drug initiation.
- Subjects on 5-alpha reductase inhibitors such as finasteride (PROSCAR®, PROPECIA®), or dutasteride (AVODART®) within 28 days of study drug initiation.
- Subjects who received any investigational agent ≤28 days of study drug initiation.
- Subjects who received palliative radiotherapy ≤2 weeks of study drug initiation.
- Subjects with symptomatic CNS metastases.
- Subjects with a history of another invasive malignancy ≤3 years of study drug initiation.
- Subjects with a QTcF interval of >470 msec; if the Screening ECG QTcF interval is >470 msec, it may be repeated, and if repeat <470 msec, the subject may be enrolled.
- Subject with clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second degree or third degree atrioventricular heart block without a permanent pacemaker in place)
- Subject that started a bone modifying agent (e.g. bisphosphonates, denosumab) ≤ 28 days of study drug initiation (note: ongoing bone modifying agents administered > 28 days are allowed).
- Subject with any medical condition that could preclude subject participation in the study, pose an undue medical hazard, or which could interfere with study results.
- Subject with Class III or IV Congestive Heart Failure as defined by the New York Heart Association (NYHA) functional classification system within the previous 6 months.
- Subject with a history of loss of consciousness or transient ischemic attack ≤ 12 months of study drug initiation.
- Subject with known active HIV, Hepatitis B, or Hepatitis C infections.
- Subject with known or suspected hypersensitivity to seviteronel, or any components of the formulation
- Subject with any other condition which in the opinion of the investigator would preclude participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prior Abiraterone or Enzalutamide
Seviteronel: given orally once daily in 28-day cycles
|
Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Other Names:
|
EXPERIMENTAL: Prior Abiraterone and Enzalutamide
Seviteronel: given orally once daily in 28-day cycles
|
Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who have a PSA response by while on study from starting treatment with seviteronel
Time Frame: 6 months
|
PSA response at any time whilst on study from the start of treatment within seviteronel defined by a ≥ 50% decrease in serum PSA.
|
6 months
|
The time to radiographic disease progression by RECIST 1.1 or PCWG3
Time Frame: 10 months
|
Median time to radiographic disease progression evaluated by computerized tomography (CT scan) or magnetic resonance imaging (MRI) and radionuclide bone scans by RECIST 1.1 or Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
|
10 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INO-VT-464-CL-003
- VMT-VT-464-CL-003 (OTHER: Innocrin)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Seviteronel: given orally once daily in 28-day cycles
-
Innocrin PharmaceuticalNational Cancer Institute (NCI)Completed
-
Innocrin PharmaceuticalCompletedCastration-resistant Prostate Cancer | CRPCUnited States
-
Innocrin PharmaceuticalCompletedCastration-resistant Prostate Cancer | CRPCUnited States, Greece, Switzerland, United Kingdom
-
Tyra Biosciences, IncRecruitingSolid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced CholangiocarcinomaUnited States
-
Meirav Kedmi MDJohnson & JohnsonUnknownDiffuse Large B Cell Lymphoma | Recurrent Disease | Refractory Cancer | Primary Mediastinal (Thymic) Large B-cell Lymphoma | Transformed Indolent LymphomaIsrael
-
ViiV HealthcareCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
Zhejiang Cancer HospitalFudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsCompletedStage III Non-small-Cell Lung CancerChina
-
Ifakara Health InstituteUniversity of OxfordNot yet recruitingControlled Human Malaria Infection | Malaria Transmission | Induced Blood Stage Malaria Infection | Malaria ChallengeTanzania
-
Swiss Federal Institute of TechnologyCompletedAnemia | Iron Deficiency Anemia | Iron DeficiencySwitzerland
-
Novartis PharmaceuticalsRecruitingFollicular Lymphoma (FL)Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Czechia, Romania, Slovakia